275 related articles for article (PubMed ID: 38459720)
1. Prevalence and risk factors of metabolic dysfunction-associated steatotic liver disease in south Central Uganda: A cross-sectional survey.
Enriquez R; Homsi M; Ssekubugu R; Nabukalu D; Zeebari Z; Marrone G; Gigante B; Chang LW; Reynolds SJ; Nalugoda F; Ekström AM; Hagström H; Nordenstedt H
Aliment Pharmacol Ther; 2024 May; 59(9):1111-1121. PubMed ID: 38459720
[TBL] [Abstract][Full Text] [Related]
2. Steatotic liver disease predicts cardiovascular disease and advanced liver fibrosis: A community-dwelling cohort study with 20-year follow-up.
Choe HJ; Moon JH; Kim W; Koo BK; Cho NH
Metabolism; 2024 Apr; 153():155800. PubMed ID: 38266957
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of steatotic liver disease, MASLD, MetALD and significant fibrosis in people with HIV in the United States.
Gawrieh S; Vilar-Gomez E; Woreta TA; Lake JE; Wilson LA; Price JC; Naggie S; Sterling RK; Heath S; Corey KE; Cachay ER; Ajmera V; Tonascia J; Sulkowski MS; Chalasani N; Loomba R
Aliment Pharmacol Ther; 2024 Mar; 59(5):666-679. PubMed ID: 38158589
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) in a middle-aged population with overweight and normal liver enzymes, and diagnostic accuracy of noninvasive proxies.
van Son KC; Te Nijenhuis-Noort LC; Boone SC; Mook-Kanamori DO; Holleboom AG; Roos PR; Lamb HJ; Alblas G; Coenraad MJ; Rosendaal FR; de Mutsert R; Tushuizen ME
Medicine (Baltimore); 2024 Jan; 103(1):e34934. PubMed ID: 38181294
[TBL] [Abstract][Full Text] [Related]
5. MASLD, hepatic steatosis and fibrosis are associated with the prevalence of chronic kidney disease and retinopathy in adults with type 1 diabetes mellitus.
Mantovani A; Morieri ML; Aldigeri R; Palmisano L; Masulli M; Bonomo K; Baroni MG; Cossu E; Cimini FA; Cavallo G; Buzzetti R; Mignogna C; Leonetti F; Bacci S; Trevisan R; Pollis RM; Cas AD; de Kreutzenberg SV; Targher G
Diabetes Metab; 2024 Jan; 50(1):101497. PubMed ID: 37992857
[TBL] [Abstract][Full Text] [Related]
6. Trends in Oxidative Balance Score and Prevalence of Metabolic Dysfunction-Associated Steatotic Liver Disease in the United States: National Health and Nutrition Examination Survey 2001 to 2018.
Tan Z; Wu Y; Meng Y; Liu C; Deng B; Zhen J; Dong W
Nutrients; 2023 Nov; 15(23):. PubMed ID: 38068789
[TBL] [Abstract][Full Text] [Related]
7. Increased visceral fat area to skeletal muscle mass ratio is positively associated with the risk of metabolic dysfunction-associated steatotic liver disease in a Chinese population.
Liu C; Li N; Sheng D; Shao Y; Qiu L; Shen C; Liu Z
Lipids Health Dis; 2024 Apr; 23(1):104. PubMed ID: 38616253
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of cardiovascular risk factors by HIV status in a population-based cohort in South Central Uganda: a cross-sectional survey.
Enriquez R; Ssekubugu R; Ndyanabo A; Marrone G; Gigante B; Chang LW; Reynolds SJ; Nalugoda F; Ekstrom AM; Sewankambo NK; Serwadda DM; Nordenstedt H
J Int AIDS Soc; 2022 Apr; 25(4):e25901. PubMed ID: 35419976
[TBL] [Abstract][Full Text] [Related]
9. Association between food insecurity and metabolic dysfunction-associated steatotic liver disease/significant fibrosis measured by fibroscan.
Kim D; Perumpail BJ; Cholankeril G; Ahmed A
Eur J Nutr; 2024 Apr; 63(3):995-1001. PubMed ID: 38260997
[TBL] [Abstract][Full Text] [Related]
10. Liver function tests and fibrosis scores in a rural population in Africa: a cross-sectional study to estimate the burden of disease and associated risk factors.
O'Hara G; Mokaya J; Hau JP; Downs LO; McNaughton AL; Karabarinde A; Asiki G; Seeley J; Matthews PC; Newton R
BMJ Open; 2020 Mar; 10(3):e032890. PubMed ID: 32234740
[TBL] [Abstract][Full Text] [Related]
11. Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease.
Lee HH; Lee HA; Kim EJ; Kim HY; Kim HC; Ahn SH; Lee H; Kim SU
Gut; 2024 Feb; 73(3):533-540. PubMed ID: 37907259
[TBL] [Abstract][Full Text] [Related]
12. Metabolic dysfunction-associated steatotic liver disease in older adults is associated with frailty and social disadvantage.
Clayton-Chubb D; Kemp WW; Majeed A; Lubel JS; Woods RL; Tran C; Ryan J; Hodge A; Schneider HG; McNeil JJ; Roberts SK
Liver Int; 2024 Jan; 44(1):39-51. PubMed ID: 37698034
[TBL] [Abstract][Full Text] [Related]
13. Extent to which weight loss contributes to improving metabolic dysfunction-associated and metabolic and alcohol related/associated steatotic liver disease: a study on Japanese participants undergoing health checkups.
Fukuda T; Okamoto T; Fukaishi T; Kawakami A; Tanaka M; Yamada T; Monzen K
Front Endocrinol (Lausanne); 2024; 15():1392280. PubMed ID: 38779448
[TBL] [Abstract][Full Text] [Related]
14. Association between Alcohol Consumption and Metabolic Dysfunction-Associated Steatotic Liver Disease Based on Alcohol Flushing Response in Men: The Korea National Health and Nutrition Examination Survey 2019-2021.
Kang DE; Oh SN
Nutrients; 2023 Sep; 15(18):. PubMed ID: 37764685
[TBL] [Abstract][Full Text] [Related]
15. Different Associations of Coffee Consumption with the Risk of Incident Metabolic Dysfunction-Associated Steatotic Liver Disease and Advanced Liver Fibrosis.
Lee JH; Park J; Ahn SB
Nutrients; 2023 Dec; 16(1):. PubMed ID: 38201969
[TBL] [Abstract][Full Text] [Related]
16. Association of Metabolic Dysfunction-Associated Steatotic Liver Disease/Non-alcoholic Fatty Liver Disease With Type 2 Diabetes Mellitus: A Case-Control Study in a Tertiary Care Hospital in Pakistan.
Zahoor F; Saeed NU; Javed S; Sadiq HZ; Mand Khan F; Haider M; Shafqat MN; Maqbool A; Chaudhry A
Cureus; 2023 Oct; 15(10):e47240. PubMed ID: 38021965
[TBL] [Abstract][Full Text] [Related]
17. Liver and atherosclerotic risks of patients with cryptogenic steatotic liver disease.
Wang SW; Hsieh TH; Cheng YM; Wang CC; Kao JH
Hepatol Int; 2024 Jun; 18(3):943-951. PubMed ID: 38227142
[TBL] [Abstract][Full Text] [Related]
18. Prevalence, distribution, and hepatic fibrosis burden of the different subtypes of steatotic liver disease in primary care settings.
Lee CM; Yoon EL; Kim M; Kang BK; Cho S; Nah EH; Jun DW
Hepatology; 2024 Jun; 79(6):1393-1400. PubMed ID: 38100294
[TBL] [Abstract][Full Text] [Related]
19. High prevalence of diabetes among young First Nations Peoples with metabolic dysfunction-associated steatotic liver disease: a population-based study in Australia.
Valery PC; Roche S; Brown C; O'Beirne J; Hartel G; Leggett B; Skoien R; Powell EE
Int J Equity Health; 2024 Apr; 23(1):84. PubMed ID: 38689295
[TBL] [Abstract][Full Text] [Related]
20. Incident cardiac arrhythmias associated with metabolic dysfunction-associated steatotic liver disease: a nationwide histology cohort study.
Simon TG; Ebrahimi F; Roelstraete B; Hagström H; Sundström J; Ludvigsson JF
Cardiovasc Diabetol; 2023 Dec; 22(1):343. PubMed ID: 38093277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
